kneat.com (TSE:KSI) Upgraded to Strong-Buy at Cibc World Mkts

Cibc World Mkts upgraded shares of kneat.com (TSE:KSI) to a strong-buy rating in a research note released on Tuesday morning, Zacks.com reports.

KSI has been the topic of a number of other research reports. Ventum Cap Mkts raised shares of kneat.com to a “strong-buy” rating in a research note on Wednesday, August 7th. CIBC set a C$6.00 price objective on kneat.com and gave the company an “outperform” rating in a research note on Tuesday.

kneat.com Price Performance

Shares of KSI stock opened at C$4.80 on Tuesday. kneat.com has a 12 month low of C$2.68 and a 12 month high of C$5.17. The company has a market capitalization of C$412.80 million, a P/E ratio of -30.00, a P/E/G ratio of 597.67 and a beta of 1.08. The stock has a 50 day moving average of C$4.76 and a two-hundred day moving average of C$4.44. The company has a current ratio of 1.47, a quick ratio of 1.50 and a debt-to-equity ratio of 95.14.

kneat.com (TSE:KSI) last issued its earnings results on Tuesday, August 6th. The company reported C($0.04) EPS for the quarter, hitting the consensus estimate of C($0.04). The firm had revenue of C$11.68 million during the quarter, compared to analysts’ expectations of C$11.45 million. kneat.com had a negative return on equity of 51.13% and a negative net margin of 31.19%. As a group, equities analysts expect that kneat.com will post -0.12 EPS for the current year.

About kneat.com

kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.